Premarket movers: Sanmina, AAON surge; Hims & Hers, Rocket Lab fall
At a glance
- $HIMS today−4.53%last $17.72
- Vs industry peers−3.05 pts6-peer median −1.49% · far behind
- Since Nov 10−21.8%from the first trade after the story
- 52-week range29.0% above low$13.74 – $40.99
- Last reported loss$33.0Mquarter to Sep 30, 2026 · 10-Q
- Coverage1 this week7 in 30 days · about its usual pace
- Key person: Filed with SEC
- Clear: legal, regulatory, security, operational, financial integrity
Options price an average move of ±17.6% by Dec 18 — the at-the-money straddle, the typical size of the move; the bands are one standard deviation.
Early signals (1) — filed with the SEC or first reported, not yet widely covered
- Key person · SEC 8-K, Item 5.02, Nov 9: Filed: a director or officer departed, was appointed, or had their pay changed. View filing →
Close-to-close moves; beta-adjusted against the S&P 500, σ in the stock’s own daily noise; ranges one standard deviation. Reports are outlets’ words or SEC filings. Not a forecast or advice.
What it means
- What to watch: In healthcare, the calendar is the catalyst: trial readouts, FDA dates and pricing rules drive most of the moves.
- How the stock is trading: $HIMS -4.53% in the latest session.
- Timing: It came out pre-market, so the next session was the first that could react.
Where the stock stands
Hims & Hers Health ($HIMS) fell 4.53% to $17.72 in the latest session. Over the past month it is down 37.0%. That leaves it 57% below its 52-week high of $40.99 and 29% above its low of $13.74. The year's high was 3.0 times its low, which makes double-digit swings fairly routine here.
What the filings say
In its latest report (10-Q, filed Nov 9, 2026), $HIMS lost $33.0M over the quarter to Sep 30, 2026 on revenue of $890.4M (+18.2% QoQ). Operations brought in $118.8M of cash over the nine months to Sep 30, 2026. Total liabilities were $3.19B against $605.6M of cash on Sep 30, 2026. The company filed an 8-K — the form for material events — on Nov 9, 1 day before this story; it is $HIMS's own account and the first thing to read. Figures are as filed with the SEC; the $HIMS page has the full statements.
How much coverage it is getting
Wook has filed 7 stories on Hims & Hers Health in the last 30 days, 1 of them this week. Its 30-day average is about 2 a week, so this week is quieter than usual. Going by their wording, 3 read bullish, 3 neutral and 1 bearish. This one reads neutral, along with a sizeable minority of them. 3 came from Investing.com and the rest from other outlets, so more than one newsroom is on it.
The bigger picture
Healthcare stories turn on approvals, trial data and pricing: one FDA decision or trial readout can swing a single drugmaker hard, while drug-pricing policy moves the whole group at once. Health Care reads calm on Wook's supply-chain scanner today, with no unusual stress in the filings and disclosures it watches.
What to watch next
The company's own filings are the primary source. Its latest SEC reports, including any filing on a material event, are on the $HIMS page, and they say what management has disclosed without a reporter in between. Reading how two or three outlets frame the same story is the quickest way to separate the facts from the angle. To run the numbers yourself, ask Wook AI above about $HIMS: its distance from the high, its last report, or how coverage has changed.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Investing.com published this on November 10, 2026. $HIMS has moved -21.77% ($22.65 to $17.72). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.
